- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.01. | Insilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotech | ||
| 20.01. | Nkarta's CEO wore head-to-toe pink at JPM. Here's why it matters more than ever | ||
| 20.01. | Former Spero execs fined by SEC over antibiotic efficacy claims | ||
| 20.01. | Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs | ||
| 20.01. | Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark | ||
| 20.01. | Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs | ||
| 20.01. | Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years | ||
| 20.01. | GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair | ||
| 19.01. | AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta | ||
| 19.01. | Immunology biotech Agomab, eye-focused SpyGlass Pharma are latest biotechs to share IPO ambitions | ||
| 16.01. | Vedanta 'significantly' reduces headcount to fund lead bacteria cocktail program | ||
| 16.01. | ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial | ||
| 15.01. | Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas | ||
| 15.01. | Italy's Alfasigma pens €125M deal for injectable form of German biotech's HSV treatment | ||
| 15.01. | All the meetings, none of the mega-deals: Is JPM's purpose evolving? | ||
| 14.01. | JPM26: With pricing deal in the books, Sanofi steels against lingering policy unknowns | ||
| 14.01. | JPM26, Day 3: Hundreds attend Biotech CEO Sisterhood meetup; Novartis CMO on why China's speed is hard to compare to US | ||
| 14.01. | Caldera launches with $112M, former Morphic CEO and IBD drug from China | ||
| 13.01. | Pretzel emerges as winner from rise and fall of Rome Therapeutics | ||
| 13.01. | JPM26, Day 2: Amgen touts MariTide's showing in exploratory weight loss maintenance study | ||
| 13.01. | JPM26: Novo Nordisk's CSO craving 'different flavors' of innovation at conference | ||
| 13.01. | NIH loses yet another leader as heart, lung and blood director exits | ||
| 13.01. | JPM26: Takeda's R&D head talks slow Monday, the biggest threat to US innovation and a phoenix rebirth | ||
| 13.01. | Lyra ditches sole rhinosinusitis asset, lays off all employees | ||
| 12.01. | AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.